Relay Therapeutics, Inc. financial data

Symbol
RLAY on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
399 Binney Street, 2 Nd Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.95K % +35.4%
Debt-to-equity 12.3 % -28.2%
Return On Equity -45.8 % -20.1%
Return On Assets -40.8 % -25.2%
Operating Margin -1.03K % +96.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 167M shares +35.8%
Common Stock, Shares, Outstanding 167M shares +35.5%
Entity Public Float 1.5B USD -16.7%
Common Stock, Value, Issued 167K USD +35.8%
Weighted Average Number of Shares Outstanding, Basic 140M shares +14.7%
Weighted Average Number of Shares Outstanding, Diluted 111M shares +19.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 35.3M USD +2874%
Revenue from Contract with Customer, Excluding Assessed Tax 35.3M USD +2874%
General and Administrative Expense 76.5M USD +2.55%
Operating Income (Loss) -380M USD -7.36%
Net Income (Loss) Attributable to Parent -345M USD -5.9%
Earnings Per Share, Basic -2.6 USD/shares +2.99%
Earnings Per Share, Diluted -2.6 USD/shares +2.99%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 152M USD +0.68%
Accounts Receivable, after Allowance for Credit Loss, Current 211K USD -12.4%
Other Assets, Current 6.8M USD +84.7%
Assets, Current 865M USD +4.01%
Property, Plant and Equipment, Net 7.21M USD -32.6%
Operating Lease, Right-of-Use Asset 53.4M USD -10.3%
Assets 930M USD +2.55%
Accounts Payable, Current 6.87M USD -48.6%
Accrued Liabilities, Current 33.2M USD +5.5%
Contract with Customer, Liability, Current 83K USD -80%
Liabilities, Current 47M USD -7.45%
Operating Lease, Liability, Noncurrent 44.3M USD -11.1%
Liabilities 91.3M USD -29%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.51M USD
Retained Earnings (Accumulated Deficit) -1.66B USD -26.2%
Stockholders' Equity Attributable to Parent 839M USD +7.77%
Liabilities and Equity 930M USD +2.55%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.3M USD +25%
Net Cash Provided by (Used in) Financing Activities 48.9M USD +3672%
Net Cash Provided by (Used in) Investing Activities 10.5M USD -86%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 167M shares +35.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.13M USD -3.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 154M USD +0.29%
Deferred Tax Assets, Valuation Allowance 300M USD +30.1%
Deferred Tax Assets, Gross 312M USD +25.8%
Depreciation 1.4M USD +16.5%
Payments to Acquire Property, Plant, and Equipment 1.78M USD -7.05%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -339M USD -7.38%
Property, Plant and Equipment, Gross 34.5M USD +14.9%
Operating Lease, Liability, Current 5.53M USD +15.5%
Deferred Tax Assets, Operating Loss Carryforwards 141M USD +18.2%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 2.5B USD +19%
Deferred Tax Assets, Net of Valuation Allowance 12.3M USD -30.3%
Share-based Payment Arrangement, Expense 95.8M USD +18.9%